Stem Cell Therapeutic and Research Reauthorization Act of 2026
Summary
What This Bill Does
The Stem Cell Therapeutic and Research Reauthorization Act of 2026 extends federal support for stem cell transplantation infrastructure. It amends the Public Health Service Act to authorize $33.009 million for the C.W. Bill Young Cell Transplantation Program for each of fiscal years 2027 through 2031. The bill also amends the Stem Cell Therapeutic and Research Act of 2005 by extending the cord blood inventory date from 2026 to 2031.
Who Benefits and How
Patients needing bone marrow, peripheral blood stem cell, or cord blood transplants benefit from continued federal support for donor and transplantation infrastructure. The C.W. Bill Young Cell Transplantation Program benefits from a five-year funding authorization. Cord blood banks and transplant centers benefit from continued federal support for cord blood inventory activities through 2031.
Who Bears the Burden and How
Federal taxpayers bear the budgetary cost of the $33.009 million annual authorization for fiscal years 2027 through 2031. Federal health program administrators bear responsibility for continuing the program and implementing the updated cord blood inventory timeline.
Key Provisions
- Authorizes $33.009 million per year for the C.W. Bill Young Cell Transplantation Program for fiscal years 2027 through 2031.
- Extends the cord blood inventory authorization date from 2026 to 2031.
Evidence Chain:
This summary is generated from the full bill text using AI analysis. Expand "Detailed Analysis" below for identified beneficiaries/burden bearers with clause-level evidence links.
At a Glance
What This Bill Does
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program at $33.009 million per year for fiscal years 2027 through 2031 and extends the cord blood inventory authorization date from 2026 to 2031.
Key Policy Areas
Health, Biomedical Research, Federal Budget
Primary Purpose
The bill reauthorizes the C.W. Bill Young Cell Transplantation Program at $33.009 million per year for fiscal years 2027 through 2031 and extends the cord blood inventory authorization date from 2026 to 2031.
Policy Domains
Stem cell transplantation and cord blood inventory reauthorization
Identified Gains
- Patients needing stem cell transplants
- C.W. Bill Young Cell Transplantation Program
- Cord blood banks
Identified Costs
- Federal taxpayers
- Federal health program administrators
Sponsors
Legislative Progress
ReportedPlaced on Senate Legislative Calendar under General Orders. Calendar No. …
Committee on Health, Education, Labor, and Pensions. Reported by Senator …
Committee on Health, Education, Labor, and Pensions. Ordered to be …
Read twice and referred to the Committee on Health, Education, …
Introduced in Senate
Mr. Reed (for himself, Mr. Scott of South Carolina, Ms. …
Stakeholder Effects
cui bono?How this legislation distributes effects. Mention counts reflect frequency, not effect magnitude.
C.W. Bill Young Cell Transplantation Program
Bill Structure & Actor Mappings
Who is "The Secretary" in each section?
- "program"
- → C.W. Bill Young Cell Transplantation Program
- "patients"
- → Patients needing stem cell transplants
- "administrators"
- → Federal health program administrators
- "cord_blood_banks"
- → Cord blood banks
Key Definitions
Terms defined in this bill
The Stem Cell Therapeutic and Research Act inventory provision whose authorization date is extended from 2026 to 2031.
The Public Health Service Act program reauthorized by the bill for fiscal years 2027 through 2031.
We use a combination of our own taxonomy and classification in addition to large language models to assess meaning and potential beneficiaries. High confidence means strong textual evidence. Always verify with the original bill text.
Learn more about our methodology